United States

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

9 Dec 2016
Change (% chg)

$-0.15 (-3.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for DVAX.OQ


Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company's lead vaccine product candidate is HEPLISAV-B, an... (more)


Beta: 1.99
Market Cap(Mil.): $184.93
Shares Outstanding(Mil.): 38.53
Dividend: --
Yield (%): --


  DVAX.OQ Industry Sector
P/E (TTM): -- 40.79 30.35
EPS (TTM): -2.87 -- --
ROI: -71.69 -0.56 15.27
ROE: -73.60 -1.20 16.60

BRIEF-Dynavax receives complete response letter from U.S. FDA

* Dynavax Technologies Corp says expects a Class 2 designation for a resubmission of BLA, which would result in a target review period of six months

Nov 14 2016

BRIEF-Dynavax reports Q3 2016 financial results and company update

* Dynavax Technologies Corp says preparations for launch of HEPLISAV-B are continuing, including pre-commercial activities

Nov 07 2016

BRIEF-Dynavax secures committed financing for $100 mln of senior secured notes

* Secures committed financing from Deerfield for $100 million of senior secured notes

Oct 27 2016

BRIEF-Steven Cohen reports 5.9 pct passive stake in Dynavax Technologies Corp

* Steven Cohen reports 5.9 percent passive stake in Dynavax Technologies Corp as of Sept. 29 - SEC filing Source text - http://bit.ly/2dio2S9 Further company coverage:

Oct 06 2016

BRIEF-Glenhill Advisors posts 5.5 pct passive stake in Dynavax Technologies - SEC Filing

* Glenhill Advisors LLC reports 5.5 pct passive stake in Dynavax Technologies as of September 7, 2016 - sec filing Source text for Eikon: (http://bit.ly/2cZkTLH) Further company coverage:

Sep 19 2016

BRIEF-U.S. FDA cancels Dynavax's Nov advisory committee meeting

* U.S. FDA says November advisory committee meeting to discuss hepatitis B vaccine from Dynavax Technologies Corp has been canceled

Sep 02 2016

BRIEF-Dynavax announces FDA advisory committee meeting to review HEPLISAV-B

* Announces FDA advisory committee meeting to review HEPLISAV-B

Aug 05 2016


Earnings vs. Estimates